Skip to main content

Find Drugs & Conditions

Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.

FDA Approves Yesafili (aflibercept-jbvf), an Interchangeable Biosimilar to Eylea

The U.S. Food and Drug Administration (FDA) has approved Yesafili (aflibercept-jbvf), an interchangeable biosimilar to Eylea (aflibercept). Aflibercept...

FDA Approves Opuviz (aflibercept-yszy), an Interchangeable Biosimilar to Eylea

The U.S. Food and Drug Administration (FDA) has approved Opuviz (aflibercept-yszy), an interchangeable biosimilar to Eylea (aflibercept). Aflibercept...

Tea Was a Real Life Saver in 18th Century England

Sipped from porcelain cups amid the music of Mozart and periwigs of the 1700s, tea was introduced to England and began its quiet work saving thousands...

Are You a 'Stress Bragger'? It's Probably Backfiring

"Ugh, I'm so busy these days I can barely think straight. It's so crazy." No doubt some friend or coworker (maybe even yourself) has moaned about how...

Moms, Even When Kids Reject Your Advice, It's Still Helping Them

Does advising your teen sometimes feel like talking to the proverbial brick wall? Don't fret: New research shows that even when your preteen or teen gives...

Had a Joint Replaced? Your Infection Risk May Rise After Chemotherapy

If you're one of the millions of Americans walking around with a new knee or hip, your odds for an infection in that joint rise if you ever have to undergo...

HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients

SOUTH SAN FRANCISCO, Calif., May 25, 2024. Human Immunology Biosciences (HI-Bio), a clinical-stage biotechnology company developing targeted therapies...

Preterm, Early-Term Birth Rates Increase After Heat Waves

Preterm and early-term birth rates increase after heat waves, according to a study published online May 24 in JAMA Network Open. Lyndsey A. Darrow, Ph.D.,...

High Mediterranean Diet Adherence Tied to Fewer Anxiety, Stress Symptoms

Adherence to a Mediterranean diet (MedDiet) is inversely associated with the severity of anxiety and stress symptoms in older adults, according to a study...

Primary HPV Screening Intervals Could Be Extended

Primary human papillomavirus (HPV) screening intervals could be extended, with the risk for cervical precancer or worse (CIN2+) eight years after negative...

Donepezil Not Beneficial for Cognitive Impairment in Breast Cancer Survivors

A once-daily dose of donepezil does not improve cognitive function among breast cancer survivors exposed to chemotherapy one to five years earlier, according...

Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of Afuresertib PLUS LAE001 for the Treatment of Prostate Cancer

SHANGHAI and WARREN, N.J., May 23, 2024. Laekna, Inc., a science-driven, clinical-stage biotechnology company, announced that the company has received...

Do Fish Oil Supplements Help or Harm the Heart?

Folks regularly taking fish oil supplements might not be helping their health as much as they might think, a new study suggests. Regular use of fish oil...

Hospira Inc. Issues Voluntary Recall for Buprenorphine HCl Injection Carpuject Units and Labetalol HCl Injection Carpuject Units Due to Potential for Incomplete Crimp Seals

May 21, 2024 - NEW YORK, NY., Hospira, Inc., a Pfizer company (“Pfizer”), is voluntarily recalling the lots listed in the table below of Buprenorphine...

Read more news...

Recently Added

Recently added consumer and prescribing information: Yesafili, Myhibbin, Rezenopy, Libervant, Beqvez, Xolremdi, Pivya, Xromi, Risvan, Voydeya

For Consumers

For Professionals

For Researchers

Latest FDA New Drug Approvals

  • Yesafili Yesafili (aflibercept-jbvf) is a vascular endothelial growth factor (VEGF) inhibitor interchangeable biosimilar to Eylea indicated for the...
  • Opuviz Opuviz (aflibercept-yszy) is a vascular endothelial growth factor (VEGF) inhibitor interchangeable biosimilar to Eylea indicated for the...
  • Imdelltra Imdelltra (tarlatamab-dlle) is a first-in-class, bispecific delta-like ligand 3 (DLL3)-directed CD3 T cell engager indicated for the...

More FDA approvals

Drugs in Development (Not yet approved)

  • Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) to...

More drugs in development